These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 16815961)
21. The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation. Nair PC; Burns K; Chau N; McKinnon RA; Miners JO J Biol Chem; 2023 Dec; 299(12):105368. PubMed ID: 37866634 [TBL] [Abstract][Full Text] [Related]
22. CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites. Ahlström MM; Ridderström M; Zamora I J Med Chem; 2007 Nov; 50(22):5382-91. PubMed ID: 17915853 [TBL] [Abstract][Full Text] [Related]
23. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Becker ML; Visser LE; Trienekens PH; Hofman A; van Schaik RH; Stricker BH Clin Pharmacol Ther; 2008 Feb; 83(2):288-92. PubMed ID: 17597710 [TBL] [Abstract][Full Text] [Related]
24. Effect of the CYP2C9*3 allele on lornoxicam metabolism. Liu YL; Zhang W; Tan ZR; Ouyang DS; Luo CH; Liu ZQ; Qiu Y; Chen Y; He YJ; Zhou G; Zhou HH Clin Chim Acta; 2006 Feb; 364(1-2):287-91. PubMed ID: 16182270 [TBL] [Abstract][Full Text] [Related]
25. A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Locuson CW; Wahlstrom JL; Rock DA; Rock DA; Jones JP Drug Metab Dispos; 2003 Jul; 31(7):967-71. PubMed ID: 12814975 [TBL] [Abstract][Full Text] [Related]
26. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. DeLozier TC; Lee SC; Coulter SJ; Goh BC; Goldstein JA J Pharmacol Exp Ther; 2005 Dec; 315(3):1085-90. PubMed ID: 16099926 [TBL] [Abstract][Full Text] [Related]
27. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9. Peng CC; Rushmore T; Crouch GJ; Jones JP Bioorg Med Chem; 2008 Apr; 16(7):4064-74. PubMed ID: 18255300 [TBL] [Abstract][Full Text] [Related]
28. Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9. Hummel MA; Tracy TS; Hutzler JM; Wahlstrom JL; Zhou Y; Rock DA J Biomol Screen; 2006 Apr; 11(3):303-9. PubMed ID: 16490777 [TBL] [Abstract][Full Text] [Related]
29. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. Iwamura A; Fukami T; Hosomi H; Nakajima M; Yokoi T Drug Metab Dispos; 2011 May; 39(5):838-46. PubMed ID: 21321060 [TBL] [Abstract][Full Text] [Related]
30. CYP2C9 structure-metabolism relationships: optimizing the metabolic stability of COX-2 inhibitors. Ahlström MM; Ridderström M; Zamora I; Luthman K J Med Chem; 2007 Sep; 50(18):4444-52. PubMed ID: 17696334 [TBL] [Abstract][Full Text] [Related]
32. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Vormfelde SV; Brockmöller J; Bauer S; Herchenhein P; Kuon J; Meineke I; Roots I; Kirchheiner J Clin Pharmacol Ther; 2009 Jul; 86(1):54-61. PubMed ID: 19369937 [TBL] [Abstract][Full Text] [Related]
33. [The inhibition of CYP2C9 isoenzyme in Cunninghamella blakesleeana AS 3. 910]. Lin LH; Huang HH; Zhang P; Zhong DF Yao Xue Xue Bao; 2006 Oct; 41(10):967-72. PubMed ID: 17184115 [TBL] [Abstract][Full Text] [Related]
34. [The influence of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of warfarin in patients with constant atrial fibrillation]. Sychev DA; Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG Klin Med (Mosk); 2007; 85(1):57-60. PubMed ID: 17419358 [TBL] [Abstract][Full Text] [Related]
35. The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Rowland A; Elliot DJ; Knights KM; Mackenzie PI; Miners JO Drug Metab Dispos; 2008 May; 36(5):870-7. PubMed ID: 18256202 [TBL] [Abstract][Full Text] [Related]
36. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Visser LE; van Schaik RH; Jan Danser AH; Hofman A; Witteman JC; van Duijn CM; Uitterlinden AG; Pols HA; Stricker BH Pharmacogenet Genomics; 2007 Jul; 17(7):473-9. PubMed ID: 17558303 [TBL] [Abstract][Full Text] [Related]
37. Kinetic analysis of effector modulation of butyrylcholinesterase-catalysed hydrolysis of acetanilides and homologous esters. Masson P; Froment MT; Gillon E; Nachon F; Lockridge O; Schopfer LM FEBS J; 2008 May; 275(10):2617-31. PubMed ID: 18422653 [TBL] [Abstract][Full Text] [Related]
38. Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9. Locuson CW; Gannett PM; Tracy TS Arch Biochem Biophys; 2006 May; 449(1-2):115-29. PubMed ID: 16545770 [TBL] [Abstract][Full Text] [Related]
39. Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Uchaipichat V; Galetin A; Houston JB; Mackenzie PI; Williams JA; Miners JO Mol Pharmacol; 2008 Oct; 74(4):1152-62. PubMed ID: 18647858 [TBL] [Abstract][Full Text] [Related]
40. Interaction of CYP2C8 and CYP2C9 genotypes modifies the risk for nonsteroidal anti-inflammatory drugs-related acute gastrointestinal bleeding. Blanco G; Martínez C; Ladero JM; Garcia-Martin E; Taxonera C; Gamito FG; Diaz-Rubio M; Agundez JA Pharmacogenet Genomics; 2008 Jan; 18(1):37-43. PubMed ID: 18216720 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]